NASDAQ:KMDA Kamada (KMDA) Stock Price, News & Analysis $6.82 -0.09 (-1.24%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Kamada Stock (NASDAQ:KMDA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kamada alerts:Sign Up Key Stats Today's Range$6.62▼$6.8950-Day Range$5.90▼$8.3352-Week Range$4.74▼$9.15Volume29,650 shsAverage Volume271,986 shsMarket Capitalization$392.24 millionP/E Ratio24.37Dividend YieldN/APrice Target$14.50Consensus RatingBuy Company OverviewKamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Read More… Kamada Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreKMDA MarketRank™: Kamada scored higher than 81% of companies evaluated by MarketBeat, and ranked 220th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKamada has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKamada has only been the subject of 1 research reports in the past 90 days.Read more about Kamada's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth39.13% Earnings GrowthEarnings for Kamada are expected to grow by 39.13% in the coming year, from $0.23 to $0.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kamada is 24.11, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.43.Price to Earnings Ratio vs. SectorThe P/E ratio of Kamada is 24.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.20.Price to Earnings Growth RatioKamada has a PEG Ratio of 0.97. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioKamada has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Kamada's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.54% of the float of Kamada has been sold short.Short Interest Ratio / Days to CoverKamada has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kamada has recently increased by 2,002.53%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKamada does not currently pay a dividend.Dividend GrowthKamada does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.54% of the float of Kamada has been sold short.Short Interest Ratio / Days to CoverKamada has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kamada has recently increased by 2,002.53%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment0.26 News SentimentKamada has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Kamada this week, compared to 2 articles on an average week.Search Interest12 people have searched for KMDA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Kamada to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kamada insiders have not sold or bought any company stock.Percentage Held by Insiders36.10% of the stock of Kamada is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.38% of the stock of Kamada is held by institutions.Read more about Kamada's insider trading history. Receive KMDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter. Email Address KMDA Stock News HeadlinesKamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025February 26 at 7:00 AM | globenewswire.comKamada LtdFebruary 25 at 9:45 AM | money.usnews.comMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.February 28, 2025 | Colonial Metals (Ad)Kamada awarded $25M 3-year contract to supply kamrab, varizig in Latin AmericaJanuary 22, 2025 | markets.businessinsider.comKamada secures $25 million Latin America contractJanuary 22, 2025 | msn.comKamada Secures $25 Million Contract for Immune Globulin Products in Latin AmericaJanuary 22, 2025 | tipranks.comKamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin AmericaJanuary 22, 2025 | globenewswire.comKamada’s Strategic Advancements and Financial Growth Support Buy RatingJanuary 10, 2025 | markets.businessinsider.comSee More Headlines KMDA Stock Analysis - Frequently Asked Questions How have KMDA shares performed this year? Kamada's stock was trading at $6.09 at the beginning of 2025. Since then, KMDA shares have increased by 10.8% and is now trading at $6.7450. View the best growth stocks for 2025 here. How were Kamada's earnings last quarter? Kamada Ltd. (NASDAQ:KMDA) announced its earnings results on Wednesday, August, 16th. The biotechnology company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. The biotechnology company had revenue of $37.44 million for the quarter, compared to the consensus estimate of $34.18 million. Kamada had a net margin of 9.92% and a trailing twelve-month return on equity of 6.30%. Who are Kamada's major shareholders? Kamada's top institutional shareholders include Renaissance Technologies LLC (1.45%), Y.D. More Investments Ltd (0.87%), Millennium Management LLC (0.55%) and Aristides Capital LLC (0.11%). How do I buy shares of Kamada? Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kamada own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kamada investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), NVIDIA (NVDA), Chipotle Mexican Grill (CMG), ASML (ASML) and Oracle (ORCL). Company Calendar Last Earnings8/16/2023Today2/28/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KMDA CIK1567529 Webwww.kamada.com Phone(728) 940-6472Fax972-8940-6473Employees360Year FoundedN/APrice Target and Rating Average Stock Price Target$14.50 High Stock Price Target$18.00 Low Stock Price Target$11.00 Potential Upside/Downside+109.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.28 Trailing P/E Ratio24.68 Forward P/E Ratio30.04 P/E Growth0.97Net Income$8.28 million Net Margins9.92% Pretax Margin10.04% Return on Equity6.30% Return on Assets4.49% Debt Debt-to-Equity RatioN/A Current Ratio4.84 Quick Ratio2.73 Sales & Book Value Annual Sales$158.38 million Price / Sales2.51 Cash Flow$0.39 per share Price / Cash Flow17.90 Book Value$4.25 per share Price / Book1.63Miscellaneous Outstanding Shares57,480,000Free Float36,730,000Market Cap$397.19 million OptionableOptionable Beta0.99 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:KMDA) was last updated on 2/28/2025 by MarketBeat.com Staff From Our Partners🚨My flagship system for just $0.99Right now, you can get a full year of my flagship trading program, Stealth Trades, for just 99 cents…Traders Agency | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredFrom $10K to $700K: The pattern is repeating (New Nvidia?)If you've ever thought "I missed Nvidia, and I'll never get another chance like that," this presentation is fo...InvestorPlace | Sponsored401K Savers Taking Advantage of “Tariffs” With Odd, 2-Word MoveYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.